PAWTUCKET, R.I., Oct. 8, 2025 /PRNewswire/ — PMG Credentialing, Inc., a national leader in credentialing and enrollment services for healthcare organizations, today announced the release of a new case study showcasing how a community health center significantly improved operational efficiency and financial performance by partnering with PMG.
Prior to engaging PMG Credentialing, the health center’s credentialing process relied heavily on manual procedures. This led to delayed application processing, frequent errors, and poor coordination between internal staff and outsourced billing partners. These inefficiencies not only strained operations but also limited the organization’s financial growth.
After evaluating several options—including in-house improvements and new software implementation — the health center chose PMG Credentialing, citing its proven track record, NCQA-accredited processes, and collaborative approach.
“After thorough evaluation, we decided to partner with PMG Credentialing, Inc., given their proven track record and comprehensive service offerings,” said the health center’s leadership team.
Since integrating PMG’s services two years ago, the health center has reported:
“This partnership has transformed our credentialing process,” said the client’s CFO. “Our payments have increased by approximately 50%, reflecting the efficiency and accuracy of the new credentialing process.”
The case study underscores PMG Credentialing’s commitment to helping healthcare organizations optimize credentialing and enrollment workflows, reduce administrative burden, and improve financial outcomes.
For more information or to learn how PMG Credentialing can support your organization, please visit www.pmgcredentialing.com.
Media Contact: Kyle Falcao, info@pmgcredentialing.com
SOURCE PMG Credentialing
ATLANTA, GA AND DOHA, QATAR / ACCESS Newswire / December 6, 2025 / Ameerex Corporation…
SEATTLE, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage…
– Data support initiation of a combination cohort in the ongoing Phase 1 clinical trial…
SPRING, Texas, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Io Therapeutics, Inc., a privately held pharmaceutical…
Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates consistent overall response rate and safety…
TUS+VEN+AZA triplet frontline therapy demonstrates high rates of efficacy and MRD-negative remissions in newly diagnosed…